These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 30841862)

  • 41. Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica.
    Viswanathan S; Wong AH; Quek AM; Yuki N
    J Neuroimmunol; 2015 May; 282():92-6. PubMed ID: 25903734
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies.
    Kitley J; Elsone L; George J; Waters P; Woodhall M; Vincent A; Jacob A; Leite MI; Palace J
    J Neurol Neurosurg Psychiatry; 2013 Aug; 84(8):918-21. PubMed ID: 23467418
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients.
    Radaelli M; Moiola L; Sangalli F; Esposito F; Barcella V; Ferrè L; Rodegher M; Colombo B; Fazio R; Martinelli V; Comi G
    Mult Scler; 2016 Apr; 22(4):511-9. PubMed ID: 26199350
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years.
    Kim SH; Kim W; Li XF; Jung IJ; Kim HJ
    Arch Neurol; 2011 Nov; 68(11):1412-20. PubMed ID: 21747007
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Trial of rituximab in three patients with neuromyelitis optica].
    Imamura H; Tanaka M; Kitagawa N; Tahara M; Oono M; Tanaka K; Konishi T
    Rinsho Shinkeigaku; 2009 Aug; 49(8):457-62. PubMed ID: 19827593
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Wang Y; Ma J; Chang H; Zhang X; Yin L
    Mult Scler Relat Disord; 2021 Oct; 55():103181. PubMed ID: 34365314
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Optimal retreatment schedule of rituximab for neuromyelitis optica spectrum disorder: A systematic review.
    Abbadessa G; Miele G; Maida E; Minervini G; Lavorgna L; Bonavita S
    Mult Scler Relat Disord; 2022 Jul; 63():103926. PubMed ID: 35661568
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.
    Pittock SJ; Berthele A; Fujihara K; Kim HJ; Levy M; Palace J; Nakashima I; Terzi M; Totolyan N; Viswanathan S; Wang KC; Pace A; Fujita KP; Armstrong R; Wingerchuk DM
    N Engl J Med; 2019 Aug; 381(7):614-625. PubMed ID: 31050279
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of mycophenolate mofetil therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis.
    Songwisit S; Kosiyakul P; Jitprapaikulsan J; Prayoonwiwat N; Ungprasert P; Siritho S
    Sci Rep; 2020 Oct; 10(1):16727. PubMed ID: 33028926
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A meta-analysis to determine the efficacy and safety of tocilizumab in neuromyelitis optica spectrum disorders.
    Xie Q; Zheng T; Sun M; Sun J; Wang M
    Mult Scler Relat Disord; 2020 Oct; 45():102421. PubMed ID: 32731203
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Compassionate open-label use of rituximab following a randomised clinical trial against neuromyelitis optica (RIN-2 study): B cell monitoring-based administration.
    Tahara M; Oeda T; Okada K; Ochi K; Maruyama H; Fukaura H; Nomura K; Shimizu Y; Nakashima I; Misu T; Umemura A; Yamamoto K; Sawada H
    Mult Scler Relat Disord; 2022 Apr; 60():103730. PubMed ID: 35287025
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder.
    Ongphichetmetha T; Jitprapaikulsan J; Siritho S; Rattanathamsakul N; Detweeratham T; Prayoonwiwat N
    Sci Rep; 2024 Feb; 14(1):3503. PubMed ID: 38347079
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Relapses shortly after rituximab treatment in neuromyelitis optica spectrum disorder.
    Shi B; Zhao M; Qiao L; Huang F; Zhou S; Wei Y; Wang J; Wang N
    Mult Scler Relat Disord; 2021 Sep; 54():103143. PubMed ID: 34273608
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The efficacy of rituximab in patients with neuromyelitis optica spectrum disorder: A real-world study from Turkey.
    Uzunköprü C; Tütüncü M; Gündüz T; Gümüş H; Şen S; Demir S; Çınar BP; Türe HS; Uygunoğlu U; Toğrol RE; Terzi M; Kürtüncü M; Özakbaş S; Tütüncü M; Beckmann Y; Siva A
    Int J Clin Pract; 2021 Jul; 75(7):e14158. PubMed ID: 33743552
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of efficacy and tolerability of first-line therapies in NMOSD.
    Poupart J; Giovannelli J; Deschamps R; Audoin B; Ciron J; Maillart E; Papeix C; Collongues N; Bourre B; Cohen M; Wiertlewski S; Outteryck O; Laplaud D; Vukusic S; Marignier R; Zephir H;
    Neurology; 2020 Apr; 94(15):e1645-e1656. PubMed ID: 32170036
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Peripheral CD19
    Ellrichmann G; Bolz J; Peschke M; Duscha A; Hellwig K; Lee DH; Linker RA; Gold R; Haghikia A
    J Neurol; 2019 Jan; 266(1):57-67. PubMed ID: 30377816
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Therapeutic response to rituximab in seropositive neuromyelitis optica: Experience from a tertiary care center in South India.
    James J; Gafoor VA; Jose J; Smita B; Balaram N
    J Neurosci Rural Pract; 2023; 14(2):327-332. PubMed ID: 37181182
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of rituximab on relapse rate and disability in neuromyelitis optica.
    Bedi GS; Brown AD; Delgado SR; Usmani N; Lam BL; Sheremata WA
    Mult Scler; 2011 Oct; 17(10):1225-30. PubMed ID: 21622594
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and Safety of Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: Evidence from Randomized Controlled Trials.
    Xue T; Yang Y; Lu Q; Gao B; Chen Z; Wang Z
    Mult Scler Relat Disord; 2020 Aug; 43():102166. PubMed ID: 32442886
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and efficacy of interleukin-6-receptor inhibitors in the treatment of neuromyelitis optica spectrum disorders: a meta-analysis.
    Kharel S; Shrestha S; Ojha R; Guragain N; Ghimire R
    BMC Neurol; 2021 Nov; 21(1):458. PubMed ID: 34814882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.